NASDAQ:MNOV

MediciNova Q4 2024 Earnings Results & Report

MediciNova logo
$1.28 -0.05 (-3.83%)
As of 02:56 PM Eastern
This is a fair market value price provided by Massive. Learn more.

MediciNova met analyst earnings expectations in its Q4 2024 results, released February 19, 2025. The company reported EPS of -$0.06 versus the -$0.06 consensus estimate.

Earnings Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call
7:00 AM ET

MediciNova EPS Results

Actual EPS
-$0.06
Consensus EPS
-$0.06
Beat/Miss
Met Expectations
One Year Ago EPS
N/A
EPS Beat Rate
6 of last 8 quarters

MediciNova Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Earnings Documents

MediciNova Q4 2024 Earnings FAQ

MediciNova (NASDAQ:MNOV) reported earnings of -$0.06 per share for Q4 2024, matching the consensus estimate of -$0.06. The report was announced on Wednesday, February 19, 2025.

MediciNova Earnings Headlines

Medicinova Inc
MediciNova to Participate in the Maxim Growth Summit
“IMPERIUM”: The #1 investment of 2027
Could a strange new bio-chip be the most transformative innovation in history? Elon Musk calls it "amazing." A NASA scientist says it's "bigger than AI." A Nobel Prize winner describes its power as "unprecedented in the history of life on Earth." Adam O'Dell, Chief Investment Strategist at Money & Markets, calls the technology Imperium. He says it's set to spark a major investment megatrend, with one small Silicon Valley company at the center.tc pixel
MediciNova stock tumbles on mixed Phase 2 NAFLD trial data
See More MediciNova Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like MediciNova? Sign up for Earnings360's daily newsletter to receive timely earnings updates on MediciNova and other key companies, straight to your email.

About MediciNova

MediciNova (NASDAQ:MNOV) is a clinical-stage biopharmaceutical company that develops small-molecule drug candidates for neurological, pulmonary and other conditions. The company is based in La Jolla, California, and conducts research and clinical development through collaborations and studies in the United States and other countries.

Its lead candidate, MN-166 (ibudilast), is being studied for several conditions, including amyotrophic lateral sclerosis, progressive multiple sclerosis and substance use disorders. MediciNova is also developing MN-001 (tipelukast) for potential uses in metabolic and fibrotic diseases. These candidates are investigational and have not been approved as medicines.

MediciNova was founded in 2000. Yuichi Iwaki, M.D., Ph.D., is the company’s founder, president and chief executive officer.

View MediciNova Profile